|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Medzhitov R: Origin and physiological
roles of inflammation. Nature. 454:428–435. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh N, Baby D, Rajguru JP, Patil PB,
Thakkannavar SS and Pujari VB: Inflammation and cancer. Ann Afr
Med. 18:121–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang YZ and Li YY: Inflammatory bowel
disease: Pathogenesis. World J Gastroenterol. 20:91–99. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choi WT, Yozu M, Miller GC, Shih AR,
Kumarasinghe P, Misdraji J, Harpaz N and Lauwers GY:
Nonconventional dysplasia in patients with inflammatory bowel
disease and colorectal carcinoma: A multicenter clinicopathologic
study. Mod Pathol. 33:933–943. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen ED, Wang D, Lauwers GY and Choi WT:
Increased histologic inflammation is an independent risk factor for
nonconventional dysplasia in ulcerative colitis. Histopathology.
81:644–652. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lukas M: Inflammatory bowel disease as a
risk factor for colorectal cancer. Dig Dis. 28:619–624. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: A meta-analysis.
Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lutgens MWMD, van Oijen MGH, van der
Heijden GJMG, Vleggaar FP, Siersema PD and Oldenburg B: Declining
risk of colorectal cancer in inflammatory bowel disease: An updated
meta-analysis of population-based cohort studies. Inflamm Bowel
Dis. 19:789–799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu F, Xia Y, Parker AS and Verma IM: IKK
biology. Immunol Rev. 246:239–253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karin M and Ben-Neriah Y: Phosphorylation
meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev
Immunol. 18:621–663. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greten FR, Eckmann L, Greten TF, Park JM,
Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation
and tumorigenesis in a mouse model of colitis-associated cancer.
Cell. 118:285–296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koliaraki V, Pasparakis M and Kollias G:
IKKβ in intestinal mesenchymal cells promotes initiation of
colitis-associated cancer. J Exp Med. 212:2235–2251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schön S, Flierman I, Ofner A, Stahringer
A, Holdt LM, Kolligs FT and Herbst A: β-catenin regulates NF-κB
activity via TNFRSF19 in colorectal cancer cells. Int J Cancer.
135:1800–1811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Popivanova BK, Kitamura K, Wu Y, Kondo T,
Kagaya T, Kaneko S, Oshima M, Fujii C and Mukaida N: Blocking
TNF-alpha in mice reduces colorectal carcinogenesis associated with
chronic colitis. J Clin Invest. 118:560–570. 2008.PubMed/NCBI
|
|
17
|
Hamilton KE, Simmons JG, Ding S, Van
Landeghem L and Lund PK: Cytokine induction of tumor necrosis
factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol
Cancer Res. 9:1718–1731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Onizawa M, Nagaishi T, Kanai T, Nagano K,
Oshima S, Nemoto Y, Yoshioka A, Totsuka T, Okamoto R, Nakamura T,
et al: Signaling pathway via TNF-alpha/NF-kappaB in intestinal
epithelial cells may be directly involved in colitis-associated
carcinogenesis. Am J Physiol Gastrointest Liver Physiol.
296:G850–G859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu Q, Man SM, Gurung P, Liu Z, Vogel P,
Lamkanfi M and Kanneganti TD: Cutting edge: STING mediates
protection against colorectal tumorigenesis by governing the
magnitude of intestinal inflammation. J Immunol. 193:4779–4782.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bozec D, Iuga AC, Roda G, Dahan S and
Yeretssian G: Critical function of the necroptosis adaptor RIPK3 in
protecting from intestinal tumorigenesis. Oncotarget.
7:46384–46400. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fukata M, Hernandez Y, Conduah D, Cohen J,
Chen A, Breglio K, Goo T, Hsu D, Xu R and Abreu MT: Innate immune
signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory
microenvironment in colitis-associated tumors. Inflamm Bowel Dis.
15:997–1006. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fukata M, Chen A, Vamadevan AS, Cohen J,
Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, et
al: Toll-like receptor-4 promotes the development of
colitis-associated colorectal tumors. Gastroenterology.
133:1869–1881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo Q, Zeng L, Tang C, Zhang Z, Chen Y and
Zeng C: TLR9 induces colitis-associated colorectal carcinogenesis
by regulating NF-κB expression levels. Oncol Lett. 20:1102020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Girondel C, Lévesque K, Langlois MJ,
Pasquin S, Saba-El-Leil MK, Rivard N, Friesel R, Servant MJ,
Gauchat JF, Lesage S and Meloche S: Loss of interleukin-17 receptor
D promotes chronic inflammation-associated tumorigenesis. Oncogene.
40:452–464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hardbower DM, Coburn LA, Asim M, Singh K,
Sierra JC, Barry DP, Gobert AP, Piazuelo MB, Washington MK and
Wilson KT: EGFR-mediated macrophage activation promotes
colitis-associated tumorigenesis. Oncogene. 36:3807–3819. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizzo A, De Mare V, Rocchi C, Stolfi C,
Colantoni A, Neurath MF, Macdonald TT, Pallone F, Monteleone G and
Fantini MC: Smad7 induces plasticity in tumor-infiltrating Th17
cells and enables TNF-alpha-mediated killing of colorectal cancer
cells. Carcinogenesis. 35:1536–1546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhat AA, Ahmad R, Uppada SB, Singh AB and
Dhawan P: Claudin-1 promotes TNF-α-induced epithelial-mesenchymal
transition and migration in colorectal adenocarcinoma cells. Exp
Cell Res. 349:119–127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawai N, Tsuji S, Tsujii M, Ito T,
Yasumaru M, Kakiuchi Y, Kimura A, Komori M, Sasaki Y, Hayashi N, et
al: Tumor necrosis factor alpha stimulates invasion of
Src-activated intestinal cells. Gastroenterology. 122:331–339.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cooks T, Pateras IS, Tarcic O, Solomon H,
Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld
N, et al: Mutant p53 prolongs NF-κB activation and promotes chronic
inflammation and inflammation-associated colorectal cancer. Cancer
Cell. 23:634–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee H, Herrmann A, Deng JH, Kujawski M,
Niu G, Li Z, Forman S, Jove R, Pardoll DM and Yu H: Persistently
activated Stat3 maintains constitutive NF-kappaB activity in
tumors. Cancer Cell. 15:283–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Atreya R and Neurath MF: Signaling
molecules: The pathogenic role of the IL-6/STAT-3 trans signaling
pathway in intestinal inflammation and in colonic cancer. Curr Drug
Targets. 9:369–374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer Cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pathria P, Gotthardt D, Prchal-Murphy M,
Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J,
Musteanu M, et al: Myeloid STAT3 promotes formation of
colitis-associated colorectal cancer in mice. OncoImmunology.
4:e9985292015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang H, Wang DH, Yang X, Sun Y and Yang
CS: Colitis-induced IL11 promotes colon carcinogenesis.
Carcinogenesis. 42:557–569. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heichler C, Scheibe K, Schmied A, Geppert
CI, Schmid B, Wirtz S, Thoma OM, Kramer V, Waldner MJ, Büttner C,
et al: STAT3 activation through IL-6/IL-11 in cancer-associated
fibroblasts promotes colorectal tumour development and correlates
with poor prognosis. Gut. 69:1269–1282. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He Z, He X, Chen Z, Ke J, He X, Yuan R,
Cai Z, Chen X, Wu X and Lan P: Activation of the mTORC1 and STAT3
pathways promotes the malignant transformation of colitis in mice.
Oncol Rep. 32:1873–1880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsumoto S, Hara T, Mitsuyama K, Yamamoto
M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S and Takada T:
Essential roles of IL-6 trans-signaling in colonic epithelial
cells, induced by the IL-6/soluble-IL-6 receptor derived from
lamina propria macrophages, on the development of
colitis-associated premalignant cancer in a murine model. J
Immunol. 184:1543–1551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rizzo A, Di Giovangiulio M, Stolfi C,
Franzè E, Fehling HJ, Carsetti R, Giorda E, Colantoni A, Ortenzi A,
Rugge M, et al: RORγt-expressing Tregs drive the growth of
colitis-associated colorectal cancer by controlling IL6 in
dendritic cells. Cancer Immunol Res. 6:1082–1092. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Putoczki TL, Thiem S, Loving A, Busuttil
RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards
KM, et al: Interleukin-11 is the dominant IL-6 family cytokine
during gastrointestinal tumorigenesis and can be targeted
therapeutically. Cancer Cell. 24:257–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L and Karin M: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stolfi C, Rizzo A, Franzè E, Rotondi A,
Fantini MC, Sarra M, Caruso R, Monteleone I, Sileri P,
Franceschilli L, et al: Involvement of interleukin-21 in the
regulation of colitis-associated colon cancer. J Exp Med.
208:2279–2290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nishina T, Deguchi Y, Ohshima D, Takeda W,
Ohtsuka M, Shichino S, Ueha S, Yamazaki S, Kawauchi M, Nakamura E,
et al: Interleukin-11-expressing fibroblasts have a unique gene
signature correlated with poor prognosis of colorectal cancer. Nat
Commun. 12:22812021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liang J, Nagahashi M, Kim EY, Harikumar
KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et
al: Sphingosine-1-phosphate links persistent STAT3 activation,
chronic intestinal inflammation, and development of
colitis-associated cancer. Cancer Cell. 23:107–120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee H, Deng J, Kujawski M, Yang C, Liu Y,
Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al:
STAT3-induced S1PR1 expression is crucial for persistent STAT3
activation in tumors. Nat Med. 16:1421–1428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kortylewski M, Kujawski M, Wang T, Wei S,
Zhang S, Pillon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al:
Inhibiting Stat3 signaling in the hematopoietic system elicits
multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park SB, Choi B, Lee BJ, Kim NJ, Jeong YA,
Joo MK, Kim HJ, Park JJ, Kim JS, Noh YS and Lee HJ: Intestinal
epithelial deletion of sphk1 prevents colitis-associated cancer
development by inhibition of epithelial STAT3 activation. Dig Dis
Sci. 65:2284–2293. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Becker C, Fantini MC, Schramm C, Lehr HA,
Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al:
TGF-beta suppresses tumor progression in colon cancer by inhibition
of IL-6 trans-signaling. Immunity. 21:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kortylewski M, Xin H, Kujawski M, Lee H,
Liu Y, Harris T, Drake C, Pardoll D and Yu H: Regulation of the
IL-23 and IL-12 balance by Stat3 signaling in the tumor
microenvironment. Cancer Cell. 15:114–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Olesch C, Sirait-Fischer E, Berkefeld M,
Fink AF, Susen RM, Ritter B, Michels BE, Steinhilber D, Greten FR,
Savai R, et al: S1PR4 ablation reduces tumor growth and improves
chemotherapy via CD8+ T cell expansion. J Clin Invest.
130:5461–5476. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tewari D, Bawari S, Sharma S, DeLiberto LK
and Bishayee A: Targeting the crosstalk between canonical
Wnt/β-catenin and inflammatory signaling cascades: A novel strategy
for cancer prevention and therapy. Pharmacol Ther. 227:1078762021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
White BD, Chien AJ and Dawson DW:
Dysregulation of Wnt/β-catenin signaling in gastrointestinal
cancers. Gastroenterology. 142:219–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bian J, Dannappel M, Wan C and Firestein
R: Transcriptional regulation of Wnt/β-catenin pathway in
colorectal cancer. Cells. 9:21252020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takayama T, Ohi M, Hayashi T, Miyanishi K,
Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S and
Niitsu Y: Analysis of K-ras, APC, and beta-catenin in aberrant
crypt foci in sporadic adenoma, cancer, and familial adenomatous
polyposis. Gastroenterology. 121:599–611. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Brown JB, Lee G, Managlia E, Grimm GR,
Dirisina R, Goretsky T, Cheresh P, Blatner NR, Khazaie K, Yang GY,
et al: Mesalamine inhibits epithelial beta-catenin activation in
chronic ulcerative colitis. Gastroenterology. 138:595–605,
605.e1-e3. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Claessen MMH, Schipper MEI, Oldenburg B,
Siersema PD, Offerhaus GJA and Vleggaar FP: WNT-pathway activation
in IBD-associated colorectal carcinogenesis: Potential biomarkers
for colonic surveillance. Cell Oncol. 32:303–310. 2010.PubMed/NCBI
|
|
58
|
Chakrabarty S, Varghese VK, Sahu P,
Jayaram P, Shivakumar BM, Pai CG and Satyamoorthy K: Targeted
sequencing-based analyses of candidate gene variants in ulcerative
colitis-associated colorectal neoplasia. Br J Cancer. 117:136–143.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ma B and Hottiger MO: Crosstalk between
Wnt/β-catenin and NF-κB signaling pathway during inflammation.
Front Immunol. 7:3782016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G
and Han YW: Fusobacterium nucleatum promotes colorectal
carcinogenesis by modulating E-cadherin/β-catenin signaling via its
FadA adhesin. Cell Host Microbe. 14:195–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wu S, Morin PJ, Maouyo D and Sears CL:
Bacteroides fragilis enterotoxin induces c-Myc expression and
cellular proliferation. Gastroenterology. 124:392–400. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Iwakura Y and Ishigame H: The IL-23/IL-17
axis in inflammation. J Clin Invest. 116:1218–1222. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang L, Yi T, Kortylewski M, Pardoll DM,
Zeng D and Yu H: IL-17 can promote tumor growth through an
IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen XW and Zhou SF: Inflammation,
cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug
Des Devel Ther. 9:2941–2946. 2015.PubMed/NCBI
|
|
65
|
Hyun YS, Han DS, Lee AR, Eun CS, Youn J
and Kim HY: Role of IL-17A in the development of colitis-associated
cancer. Carcinogenesis. 33:931–936. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Langowski JL, Zhang X, Wu L, Mattson JD,
Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M:
IL-23 promotes tumour incidence and growth. Nature. 442:461–465.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Popa C, Netea MG, van Riel PLCM, van der
Meer JWM and Stalenhoef AFH: The role of TNF-alpha in chronic
inflammatory conditions, intermediary metabolism, and
cardiovascular risk. J Lipid Res. 48:751–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chen G and Goeddel DV: TNF-R1 signaling: A
beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Balkwill F: TNF-alpha in promotion and
progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Seidelin JB and Nielsen OH: Continuous
cytokine exposure of colonic epithelial cells induces DNA damage.
Eur J Gastroenterol Hepatol. 17:363–369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Porter RJ, Arends MJ, Churchhouse AMD and
Din S: Inflammatory bowel disease-associated colorectal cancer:
Translational risks from mechanisms to medicines. J Crohns Colitis.
15:2131–2141. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Huycke MM, Abrams V and Moore DR:
Enterococcus faecalis produces extracellular superoxide and
hydrogen peroxide that damages colonic epithelial cell DNA.
Carcinogenesis. 23:529–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kay J, Thadhani E, Samson L and Engelward
B: Inflammation-induced DNA damage, mutations and cancer. DNA
Repair (Amst). 83:1026732019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Rachmilewitz D, Stamler JS, Bachwich D,
Karmeli F, Ackerman Z and Podolsky DK: Enhanced colonic nitric
oxide generation and nitric oxide synthase activity in ulcerative
colitis and Crohn's disease. Gut. 36:718–723. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Meira LB, Bugni JM, Green SL, Lee CW, Pang
B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline
JL, et al: DNA damage induced by chronic inflammation contributes
to colon carcinogenesis in mice. J Clin Invest. 118:2516–2525.
2008.PubMed/NCBI
|
|
77
|
Rajamäki K, Taira A, Katainen R, Välimäki
N, Kuosmanen A, Plaketti RM, Seppälä TT, Ahtiainen M, Wirta EV,
Vartiainen E, et al: Genetic and epigenetic characteristics of
inflammatory bowel disease-associated colorectal cancer.
Gastroenterology. 161:592–607. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Burmer GC, Rabinovitch PS, Haggitt RC,
Crispin DA, Brentnall TA, Kolli VR, Stevens AC and Rubin CE:
Neoplastic progression in ulcerative colitis: Histology, DNA
content, and loss of a p53 allele. Gastroenterology. 103:1602–1610.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yaeger R, Shah MA, Miller VA, Kelsen JR,
Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, et al:
Genomic alterations observed in colitis-associated cancers are
distinct from those found in sporadic colorectal cancers and vary
by type of inflammatory bowel disease. Gastroenterology.
151:278–287.e6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hussain SP, Amstad P, Raja K, Ambs S,
Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi
AJ and Harris CC: Increased p53 mutation load in noncancerous colon
tissue from ulcerative colitis: A cancer-prone chronic inflammatory
disease. Cancer Res. 60:3333–3337. 2000.PubMed/NCBI
|
|
81
|
Rabinovitch PS, Dziadon S, Brentnall TA,
Emond MJ, Crispin DA, Haggitt RC and Bronner MP: Pancolonic
chromosomal instability precedes dysplasia and cancer in ulcerative
colitis. Cancer Res. 59:5148–5153. 1999.PubMed/NCBI
|
|
82
|
Redston MS, Papadopoulos N, Caldas C,
Kinzler KW and Kern SE: Common occurrence of APC and K-ras gene
mutations in the spectrum of colitis-associated neoplasias.
Gastroenterology. 108:383–392. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kraus S and Arber N: Inflammation and
colorectal cancer. Curr Opin Pharmacol. 9:405–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mármol I, Sánchez-de-Diego C, Pradilla
Dieste A, Cerrada E and Rodriguez Yoldi M: Colorectal carcinoma: A
general overview and future perspectives in colorectal cancer. Int
J Mol Sci. 18:1972017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Rubin CE, Haggitt RC, Burmer GC, Brentnall
TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR and
Rabinovitch PS: DNA aneuploidy in colonic biopsies predicts future
development of dysplasia in ulcerative colitis. Gastroenterology.
103:1611–1620. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Carethers JM: Screening for colorectal
cancer in African Americans: Determinants and rationale for an
earlier age to commence screening. Dig Dis Sci. 60:711–721. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Colotta F, Allavena P, Sica A, Garlanda C
and Mantovani A: Cancer-related inflammation, the seventh hallmark
of cancer: Links to genetic instability. Carcinogenesis.
30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Fujiwara I, Yashiro M, Kubo N, Maeda K and
Hirakawa K: Ulcerative colitis-associated colorectal cancer is
frequently associated with the microsatellite instability pathway.
Dis Colon Rectum. 51:1387–1394. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Din S, Wong K, Mueller MF, Oniscu A,
Hewinson J, Black CJ, Miller ML, Jiménez-Sánchez A, Rabbie R,
Rashid M, et al: Mutational analysis identifies therapeutic
biomarkers in inflammatory bowel disease-associated colorectal
cancers. Clin Cancer Res. 24:5133–5142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sato F, Harpaz N, Shibata D, Xu Y, Yin J,
Mori Y, Zou TT, Wang S, Desai K, Leytin A, et al: Hypermethylation
of the p14(ARF) gene in ulcerative colitis-associated colorectal
carcinogenesis. Cancer Res. 62:1148–1151. 2002.PubMed/NCBI
|
|
91
|
Azarschab P, Porschen R, Gregor M, Blin N
and Holzmann K: Epigenetic control of the E-cadherin gene (CDH1) by
CpG methylation in colectomy samples of patients with ulcerative
colitis. Genes Chromosomes Cancer. 35:121–126. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kuester D, Guenther T, Biesold S, Hartmann
A, Bataille F, Ruemmele P, Peters B, Meyer F, Schubert D, Bohr UR,
et al: Aberrant methylation of DAPK in long-standing ulcerative
colitis and ulcerative colitis-associated carcinoma. Pathol Res
Pract. 206:616–624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Vincan E and Barker N: The upstream
components of the Wnt signalling pathway in the dynamic EMT and MET
associated with colorectal cancer progression. Clin Exp Metastasis.
25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kinchen J, Chen HH, Parikh K,
Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, Ashley N, Cubitt
L, Mellado-Gomez E, Attar M, et al: Structural remodeling of the
human colonic mesenchyme in inflammatory bowel disease. Cell.
175:372–386.e17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lin WW and Karin M: A cytokine-mediated
link between innate immunity, inflammation, and cancer. J Clin
Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Thiesen S, Janciauskiene S, Uronen-Hansson
H, Agace W, Högerkorp CM, Spee P, Håkansson K and Grip O:
CD14(hi)HLA-DR(dim) macrophages, with a resemblance to classical
blood monocytes, dominate inflamed mucosa in Crohn's disease. J
Leukoc Biol. 95:531–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ruffell B, Affara NI and Coussens LM:
Differential macrophage programming in the tumor microenvironment.
Trends Immunol. 33:119–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gordon S: Alternative activation of
macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Biswas SK, Gangi L, Paul S, Schioppa T,
Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F,
et al: A distinct and unique transcriptional program expressed by
tumor-associated macrophages (defective NF-kappaB and enhanced
IRF-3/STAT1 activation). Blood. 107:2112–2122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Dinapoli MR, Calderon CL and Lopez DM: The
altered tumoricidal capacity of macrophages isolated from
tumor-bearing mice is related to reduce expression of the inducible
nitric oxide synthase gene. J Exp Med. 183:1323–1329. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Yang Y, Li L, Xu C, Wang Y, Wang Z, Chen
M, Jiang Z, Pan J, Yang C, Li X, et al: Cross-talk between the gut
microbiota and monocyte-like macrophages mediates an inflammatory
response to promote colitis-associated tumourigenesis. Gut.
70:1495–1506. 2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang Y, Sime W, Juhas M and Sjölander A:
Crosstalk between colon cancer cells and macrophages via
inflammatory mediators and CD47 promotes tumour cell migration. Eur
J Cancer. 49:3320–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Martinez FO, Sica A, Mantovani A and
Locati M: Macrophage activation and polarization. Front Biosci.
13:453–461. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
105
|
Maisonneuve C, Tsang DKL, Foerster EG,
Robert LM, Mukherjee T, Prescott D, Tattoli I, Lemire P, Winer DA,
Winer S, et al: Nod1 promotes colorectal carcinogenesis by
regulating the immunosuppressive functions of tumor-infiltrating
myeloid cells. Cell Rep. 34:1086772021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ibrahim ML, Klement JD, Lu C, Redd PS,
Xiao W, Yang D, Browning DD, Savage NM, Buckhaults PJ, Morse HC III
and Liu K: Myeloid-derived suppressor cells produce IL-10 to elicit
DNMT3b-dependent IRF8 silencing to promote colitis-associated colon
tumorigenesis. Cell Rep. 25:3036–3046.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Bronte V, Serafini P, Apolloni E and
Zanovello P: Tumor-induced immune dysfunctions caused by myeloid
suppressor cells. J Immunother. 24:431–446. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Katoh H, Wang D, Daikoku T, Sun H, Dey SK
and Dubois RN: CXCR2-expressing myeloid-derived suppressor cells
are essential to promote colitis-associated tumorigenesis. Cancer
Cell. 24:631–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE,
Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid
suppressor cells mediate the development of tumor-induced T
regulatory cells and T-cell anergy in tumor-bearing host. Cancer
Res. 66:1123–1131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Sinha P, Clements VK, Bunt SK, Albelda SM
and Ostrand-Rosenberg S: Cross-talk between myeloid-derived
suppressor cells and macrophages subverts tumor immunity toward a
type 2 response. J Immunol. 179:977–983. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang
Z, Wang C, Zhang Z, Xia W, et al: γδT17 cells promote the
accumulation and expansion of myeloid-derived suppressor cells in
human colorectal cancer. Immunity. 40:785–800. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Sade-Feldman M, Kanterman J, Ish-Shalom E,
Elnekave M, Horwitz E and Baniyash M: Tumor necrosis factor-α
blocks differentiation and enhances suppressive activity of
immature myeloid cells during chronic inflammation. Immunity.
38:541–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
He D, Li H, Yusuf N, Elmets CA, Li J,
Mountz JD and Xu H: IL-17 promotes tumor development through the
induction of tumor promoting microenvironments at tumor sites and
myeloid-derived suppressor cells. J Immunol. 184:2281–2288. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Ohkura N, Kitagawa Y and Sakaguchi S:
Development and maintenance of regulatory T cells. Immunity.
38:414–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wang Z, Friedrich C, Hagemann SC, Korte
WH, Goharani N, Cording S, Eberl G, Sparwasser T and Lochner M:
Regulatory T cells promote a protective Th17-associated immune
response to intestinal bacterial infection with C. rodentium.
Mucosal Immunol. 7:1290–1301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Chang LY, Lin YC, Mahalingam J, Huang CT,
Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, et al:
Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of
CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res.
72:1092–1102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kryczek I, Wu K, Zhao E, Wei S, Vatan L,
Szeliga W, Huang E, Greenson J, Chang A, Roliński J, et al: IL-17+
regulatory T cells in the microenvironments of chronic inflammation
and cancer. J Immunol. 186:4388–4395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Blatner NR, Mulcahy MF, Dennis KL,
Scholtens D, Bentrem DJ, Phillips JD, Ham S, Sandall BP, Khan MW,
Mahvi DM, et al: Expression of RORγt marks a pathogenic regulatory
T cell subset in human colon cancer. Sci Transl Med.
4:164ra1592012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Olguín JE, Medina-Andrade I, Molina E,
Vázquez A, Pacheco-Fernández T, Saavedra R, Pérez-Plasencia C,
Chirino YI, Vaca-Paniagua F, Arias-Romero LE, et al: Early and
partial reduction in CD4+Foxp3+ regulatory T
cells during colitis-associated colon cancer induces
CD4+ and CD8+ T cell activation inhibiting
tumorigenesis. J Cancer. 9:239–249. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Koliaraki V, Roulis M and Kollias G: Tpl2
regulates intestinal myofibroblast HGF release to suppress
colitis-associated tumorigenesis. J Clin Invest. 122:4231–4242.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Neufert C, Becker C, Türeci Ö, Waldner MJ,
Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, et al:
Tumor fibroblast-derived epiregulin promotes growth of
colitis-associated neoplasms through ERK. J Clin Invest.
123:1428–1443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sasaki S, Baba T, Shinagawa K, Matsushima
K and Mukaida N: Crucial involvement of the CCL3-CCR5 axis-mediated
fibroblast accumulation in colitis-associated carcinogenesis in
mice. Int J Cancer. 135:1297–1306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Kawamura T, Yamamoto M, Suzuki K, Suzuki
Y, Kamishima M, Sakata M, Kurachi K, Setoh M, Konno H and Takeuchi
H: Tenascin-C produced by intestinal myofibroblasts promotes
colitis-associated cancer development through angiogenesis. Inflamm
Bowel Dis. 25:732–741. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Fujita M, Ito-Fujita Y, Iyoda T, Sasada M,
Okada Y, Ishibashi K, Osawa T, Kodama H, Fukai F and Suzuki H:
Peptide TNIIIA2 Derived from tenascin-C contributes to malignant
progression in colitis-associated colorectal cancer via β1-integrin
activation in fibroblasts. Int J Mol Sci. 20:27522019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bai YP, Shang K, Chen H, Ding F, Wang Z,
Liang C, Xu Y, Sun MH and Li YY: FGF-1/-3/FGFR4 signaling in
cancer-associated fibroblasts promotes tumor progression in colon
cancer through Erk and MMP-7. Cancer Sci. 106:1278–1287. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hamilton KE, Chatterji P, Lundsmith ET,
Andres SF, Giroux V, Hicks PD, Noubissi FK, Spiegelman VS and
Rustgi AK: Loss of stromal IMP1 promotes a tumorigenic
microenvironment in the colon. Mol Cancer Res. 13:1478–1486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ma X, Aoki T, Tsuruyama T and Narumiya S:
Definition of prostaglandin E2-EP2 signals in the colon tumor
microenvironment that amplify inflammation and tumor growth. Cancer
Res. 75:2822–2832. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Natividad JMM and Verdu EF: Modulation of
intestinal barrier by intestinal microbiota: Pathological and
therapeutic implications. Pharmacol Res. 69:42–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Slack E, Hapfelmeier S, Stecher B,
Velykoredko Y, Stoel M, Lawson MA, Geuking MB, Beutler B, Tedder
TF, Hardt WD, et al: Innate and adaptive immunity cooperate
flexibly to maintain host-microbiota mutualism. Science.
325:617–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Nagao-Kitamoto H, Kitamoto S and Kamada N:
Inflammatory bowel disease and carcinogenesis. Cancer Metastasis
Rev. 41:301–316. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Fantini MC and Guadagni I: From
inflammation to colitis-associated colorectal cancer in
inflammatory bowel disease: Pathogenesis and impact of current
therapies. Dig Liver Dis. 53:558–565. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
LeBlanc JG, Laiño JE, del Valle MJ,
Vannini V, van Sinderen D, Taranto MP, de Valdez GF, de Giori GS
and Sesma F: B-group vitamin production by lactic acid
bacteria-current knowledge and potential applications. J Appl
Microbiol. 111:1297–1309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Quaglio AEV, Grillo TG, De Oliveira ECS,
Stasi LCD and Sassaki LY: Gut microbiota, inflammatory bowel
disease and colorectal cancer. World J Gastroenterol. 28:4053–4060.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Thursby E and Juge N: Introduction to the
human gut microbiota. Biochem J. 474:1823–1836. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Yan H and Ajuwon KM: Butyrate modifies
intestinal barrier function in IPEC-J2 cells through a selective
upregulation of tight junction proteins and activation of the Akt
signaling pathway. PLoS One. 12:e01795862017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Isobe J, Maeda S, Obata Y, Iizuka K,
Nakamura Y, Fujimura Y, Kimizuka T, Hattori K, Kim YG, Morita T, et
al: Commensal-bacteria-derived butyrate promotes the
T-cell-independent IgA response in the colon. Int Immunol.
32:243–258. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Gomaa EZ: Human gut microbiota/microbiome
in health and diseases: A review. Antonie Van Leeuwenhoek.
113:2019–2040. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kinnebrew MA, Ubeda C, Zenewicz LA, Smith
N, Flavell RA and Pamer EG: Bacterial flagellin stimulates
Toll-like receptor 5-dependent defense against vancomycin-resistant
Enterococcus infection. J Infect Dis. 201:534–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Furusawa Y, Obata Y, Fukuda S, Endo TA,
Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, et
al: Commensal microbe-derived butyrate induces the differentiation
of colonic regulatory T cells. Nature. 504:446–450. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Zhang M, Zhou Q, Dorfman RG, Huang X, Fan
T, Zhang H, Zhang J and Yu C: Butyrate inhibits interleukin-17 and
generates Tregs to ameliorate colorectal colitis in rats. BMC
Gastroenterol. 16:842016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zimmerman MA, Singh N, Martin PM,
Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH
and Liu K: Butyrate suppresses colonic inflammation through
HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T
cells. Am J Physiol Gastrointest Liver Physiol. 302:G1405–G1415.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Janeway CA Jr: Approaching the asymptote?
Evolution and revolution in immunology. Cold Spring Harb Symp Quant
Biol. 54:1–13. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kawai T and Akira S: Toll-like receptors
and their crosstalk with other innate receptors in infection and
immunity. Immunity. 34:637–650. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Cario E and Podolsky DK: Differential
alteration in intestinal epithelial cell expression of toll-like
receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect
Immun. 68:7010–7017. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Fukata M, Shang L, Santaolalla R,
Sotolongo J, Pastorini C, España C, Ungaro R, Harpaz N, Cooper HS,
Elson G, et al: Constitutive activation of epithelial TLR4 augments
inflammatory responses to mucosal injury and drives
colitis-associated tumorigenesis. Inflamm Bowel Dis. 17:1464–1473.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Frantz AL, Rogier EW, Weber CR, Shen L,
Cohen DA, Fenton LA, Bruno ME and Kaetzel CS: Targeted deletion of
MyD88 in intestinal epithelial cells results in compromised
antibacterial immunity associated with downregulation of polymeric
immunoglobulin receptor, mucin-2, and antibacterial peptides.
Mucosal Immunol. 5:501–512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ahmed I, Roy BC, Khan SA, Septer S and
Umar S: Microbiome, metabolome and inflammatory bowel disease.
Microorganisms. 4:202016. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Parekh PJ, Balart LA and Johnson DA: The
influence of the gut microbiome on obesity, metabolic syndrome and
gastrointestinal disease. Clin Transl Gastroenterol. 6:e912015.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Ghouri YA, Tahan V and Shen B: Secondary
causes of inflammatory bowel diseases. World J Gastroenterol.
26:3998–4017. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Richard ML, Liguori G, Lamas B, Brandi G,
da Costa G, Hoffmann TW, Pierluigi Di Simone M, Calabrese C,
Poggioli G, Langella P, et al: Mucosa-associated microbiota
dysbiosis in colitis associated cancer. Gut Microbes. 9:131–142.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Muller M, Hansmannel F, Arnone D, Choukour
M, Ndiaye NC, Kokten T, Houlgatte R and Peyrin-Biroulet L: Genomic
and molecular alterations in human inflammatory bowel
disease-associated colorectal cancer. United European Gastroenterol
J. 8:675–684. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Pan HW, Du LT, Li W, Yang YM, Zhang Y and
Wang CX: Biodiversity and richness shifts of mucosa-associated gut
microbiota with progression of colorectal cancer. Res Microbiol.
171:107–114. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Proença MA, Biselli JM, Succi M, Severino
FE, Berardinelli GN, Caetano A, Reis RM, Hughes DJ and Silva AE:
Relationship between Fusobacterium nucleatum, inflammatory
mediators and microRNAs in colorectal carcinogenesis. World J
Gastroenterol. 24:5351–5365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Tahara T, Hirata I, Nakano N, Tahara S,
Horiguchi N, Kawamura T, Okubo M, Ishizuka T, Yamada H, Yoshida D,
et al: Potential link between Fusobacterium enrichment and DNA
methylation accumulation in the inflammatory colonic mucosa in
ulcerative colitis. Oncotarget. 8:61917–61926. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Geis AL, Fan H, Wu X, Wu S, Huso DL, Wolfe
JL, Sears CL, Pardoll DM and Housseau F: Regulatory T-cell response
to enterotoxigenic Bacteroides fragilis colonization triggers
IL17-dependent colon carcinogenesis. Cancer Discov. 5:1098–1109.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Wick EC, Rabizadeh S, Albesiano E, Wu X,
Wu S, Chan J, Rhee KJ, Ortega G, Huso DL, Pardoll D, et al: Stat3
activation in murine colitis induced by enterotoxigenic Bacteroides
fragilis. Inflamm Bowel Dis. 20:821–834. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Purcell RV, Permain J and Keenan JI:
Enterotoxigenic Bacteroides fragilis activates IL-8 expression
through Stat3 in colorectal cancer cells. Gut Pathog. 14:162022.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Wu S, Rhee KJ, Albesiano E, Rabizadeh S,
Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, et al: A
human colonic commensal promotes colon tumorigenesis via activation
of T helper type 17 T cell responses. Nat Med. 15:1016–1022. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Arthur JC, Perez-Chanona E, Mühlbauer M,
Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B,
Rogers AB, et al: Intestinal inflammation targets cancer-inducing
activity of the microbiota. Science. 338:120–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
de Almeida CV, Taddei A and Amedei A: The
controversial role of Enterococcus faecalis in colorectal cancer.
Therap Adv Gastroenterol. 11:17562848187836062018. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Cao Y, Oh J, Xue M, Huh WJ, Wang J,
Gonzalez-Hernandez JA, Rice TA, Martin AL, Song D, Crawford JM, et
al: Commensal microbiota from patients with inflammatory bowel
disease produce genotoxic metabolites. Science. 378:eabm32332022.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Vallée A, Lecarpentier Y and Vallée JN:
Targeting the canonical WNT/β-catenin pathway in cancer treatment
using non-steroidal anti-inflammatory drugs. Cells. 8:7262019.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Dihlmann S and von Knebel Doeberitz M:
Wnt/beta-catenin-pathway as a molecular target for future
anti-cancer therapeutics. Int J Cancer. 113:515–524. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Dihlmann S, Siermann A and von Knebel
Doeberitz M: The nonsteroidal anti-inflammatory drugs aspirin and
indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene.
20:645–653. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Tuynman JB, Vermeulen L, Boon EM, Kemper
K, Zwinderman AH, Peppelenbosch MP and Richel DJ: Cyclooxygenase-2
inhibition inhibits c-Met kinase activity and Wnt activity in colon
cancer. Cancer Res. 68:1213–1220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Sonu I, Lin MV, Blonski W and Lichtenstein
GR: Clinical pharmacology of 5-ASA compounds in inflammatory bowel
disease. Gastroenterol Clin North Am. 39:559–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Graham PM, Li JZ, Dou X, Zhu H, Misra HP,
Jia Z and Li Y: Protection against peroxynitrite-induced DNA damage
by mesalamine: Implications for anti-inflammation and anti-cancer
activity. Mol Cell Biochem. 378:291–298. 2013. View Article : Google Scholar : PubMed/NCBI
|
